JSP
PACB icon

Jackson Square Partners’s Pacific Biosciences PACB Stock Holding History

Jackson Square Partners’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-553,103
Closed -$686K – 54
2025
Q2 		$686K Sell
553,103
-2,767,258
-83% -$3.2M 0.25% 54
2025
Q1 		$3.92M Sell
3,320,361
-1,788,905
-35% -$2.74M 0.53% 48
2024
Q4 		$9.35M Sell
5,109,266
-1,186,850
-19% -$2.32M 0.97% 36
2024
Q3 		$10.7M Sell
6,296,116
-2,587,327
-29% -$4.25M 0.92% 35
2024
Q2 		$12.2M Buy
8,883,443
+1,699,130
+24% +$3.43M 0.74% 36
2024
Q1 		$26.9M Sell
7,184,313
-2,520,453
-26% -$14.8M 1.12% 34
2023
Q4 		$95.2M Buy
9,704,766
+2,770,901
+40% +$22.7M 3.09% 12
2023
Q3 		$57.9M Sell
6,933,865
-1,583,759
-19% -$18.1M 1.93% 23
2023
Q2 		$113M Sell
8,517,624
-3,580,337
-30% -$43.5M 3.3% 12
2023
Q1 		$140M Sell
12,097,961
-2,907,216
-19% -$28.9M 3.79% 9
2022
Q4 		$123M Sell
15,005,177
-5,252,922
-26% -$45.3M 3.27% 13
2022
Q3 		$118M Sell
20,258,099
-2,503,943
-11% -$14.4M 3.08% 11
2022
Q2 		$101M Buy
22,762,042
+219,453
+1% +$1.33M 2.35% 20
2022
Q1 		$205M Buy
22,542,589
+8,039,420
+55% +$92.6M 2.04% 13
2021
Q4 		$297M Sell
14,503,169
-33,502
-0.2% -$809K 2.49% 10
2021
Q3 		$371M Sell
14,536,671
-299,823
-2% -$8.88M 2.35% 11
2021
Q2 		$519M Buy
14,836,494
+1,924,799
+15% +$56M 2.96% 3
2021
Q1 		$430M Sell
12,911,695
-562,743
-4% -$19.7M 2.44% 8
2020
Q4 		$350M Buy
+13,474,438
New +$229M 1.39% 30

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Jackson Square Partners's PACB Position: Q3 2025 in Review

Jackson Square Partners sold out of Pacific Biosciences (PACB) in Q3 2025, closing a stake of 553,103 shares — an estimated $686K sold.

Jackson Square Partners first reported a position in PACB in Q4 2020 and held it in 19 quarters. The position peaked at $519M in Q2 2021. 208 funds tracked by Wall St. Rank hold PACB as of Q3 2025.

  • Jackson Square Partners reported no remaining Pacific Biosciences position as of Q3 2025 after selling out during the quarter.
  • Jackson Square Partners sold 553,103 Pacific Biosciences shares in Q3 2025, an estimated $686K.
  • Jackson Square Partners first reported a position in Pacific Biosciences in Q4 2020 and held it in 19 quarters.
  • Jackson Square Partners's Pacific Biosciences position peaked at $519M in Q2 2021.
  • 208 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2025.

Based on Jackson Square Partners's 13F filing for Q3 2025, filed 5 Nov 2025.